Table 5 Overview of literature on CSI
Trial | Design | Outcome |
|---|---|---|
Grossman et al. | IT MTX versus thiotepa (59 patients; solid tumors and lymphoma) | OS, 15.9 (MTX) versus 14.1 weeks (thiotepa) |
Hitchins et al. | IT MTX versus MTX + CYT (44 patients; solid tumors and lymphoma) | OS, 12 (MTX) versus 7 weeks (MTX + CYT) |
Glantz et al. | LS-CYT versus MTX (61 patients; solid tumors) | OS, 105 (LS-CYT) versus 78 days (MTX), difference not significant |
Glantz et al. | LS-CYT versus CYT (28 patients; lymphoma) | OS, 99.5 (LS-CYT) versus 63 days (CYT), difference not significant.Cytologic response rate 71% (LS-CYT) versus 15% |
Boogerd et al. | IT versus no IT therapy, but systemic therapy and RT were given in both arms (35 patients; breast cancer) | OS, 18.3 (IT) versus 30.3 weeks (no IT) |
Shapiro et al. | Lymphoma (25 patients) | LS-CYT versus all MTX and CYT-treated patients combined: PFS 35 versus 43 days (not significant) |
LS-CYT versus MTX: PFS 35versus 37.5 days (notsignificant) |